Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

Fabian Frontzek(Spinal Cord Injury BC), Georg Lenz(Charité - Universitätsmedizin Berlin)
Nature Communications
August 31, 2021
10.1038/s41467-021-25405-w
Cited by 49

Related Papers

Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
|Nature|2010|1.6k
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
|New England Journal of Medicine|2010|1.3k
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
|Proceedings of the National Academy of Sciences|2008|985
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|971